Background: A direct association between human cytomegalovirus (HCMV) infection and the development of restenosis after coronary angioplasty has been suggested. The aim of this prospective study was to evaluate the value of HCMV serology in predicting the clinical outcome after percutaneous transluminal coronary angioplasty (PTCA). Methods and Results: 112 patients undergoing elective PTCA were included in the study. HCMV antibody levels were measured by ELISA. Cardiac events within a follow-up period of 6 months after PTCA were defined as (1) progression or recurrence of anginal complaints and/or a positive exercise test; (2) restenosis that required repeat revascularization. 73% of PTCA patients were seropositive for HCMV. Successful PTCA was achieved in a total of 94 patients, who were followed for 6 months. In 31/94 patients (33%) cardiac events occurred and in 15/94 (16%), this could be related to restenosis. We found no statistically significant difference between seropositive and negative patients with respect to anginal complaints or the need for revascularization. There was no evidence of acute reactivation, since titers of anti-HCMV antibodies did not increase after PTCA. Conclusion: This study shows that the clinical outcome after PTCA is not related to the HCMV serostatus of the patient. Therefore, our data do not support the hypothesis that serological markers of HCMV infection are of clinical importance for the assessment of a patient’s individual risk after PTCA. This does not preclude a role for local reactivation of HCMV at the site of angioplasty.

Keywords:
Angioplasty, Cytomegalovirus, Restenosis, Clinical outcome
1.
Serruys PW, Luijten HE, Beatt KJ, Geuskens R, de Feyter PJ, van den Brand M, Reiber JH, ten Katen HJ, van Es GA, Hugenholtz PG: Incidence of restenosis after successful coronary angioplasty: A time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation 1988;77:361–371.
2.
Faxon DP, Currier JW: Prevention of post-PTCA restenosis. Ann NY Acad Sci 1995;748:419–427.
3.
Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK: A cascade model for restenosis. A special case of atherosclerosis progression. Circulation 1992;86:47–52.
4.
Melnick JL, Adam E, DeBakey ME: Cytomegalovirus and atherosclerosis. Eur Heart J 1993;14(suppl K):30–38.
5.
Speir E, Modali R, Huang E-S, Leon MB, Shawl F, Finkel T, Epstein SE: Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 1994;265:391–394.
6.
Melnick JL, Dreesman GR, McCollum CH, Petrie BL, Burek J, DeBakey ME: Cytomegalovirus antigen within human arterial smooth muscle cells. Lancet 1983;ii:644–647.
7.
Petrie BL, Melnick JL, Adam E, Burek J, McCollum CH, DeBakey ME: Nucleic acid sequences of cytomegalovirus in cells from human arterial tissue. J Infect Dis 1987;155:158–159.
8.
Hendrix MG, Salimans MM, van Boven CP, Bruggeman CA: High prevalence of latently present cytomegalovirus in arterial walls of patients suffering from grade III atherosclerosis. Am J Pathol 1990;136:23–28.
9.
Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE: Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989;261:3561–3566.
10.
Lemström K, Koskinen P, Krogerus L, Daemen M, Bruggeman C, Häyry P: Cytomegalovirus antigen expression, endothelial cell proliferation, and intimal thickening in rat cardiac allografts after cytomegalovirus infection. Circulation 1995;92:2594–2604.
11.
Zhu H, Shen YQ, Shenk T: Human cytomegalovirus IE1 and IE2 proteins block apoptosis. J Virol 1995;69:7960–7970.
12.
Zhou YF, Leon MB, Waclawiw MA, Popma JJ, Yu ZX, Finkel T, Epstein SE: Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med 1996;335:624–630.
13.
Topol EJ, Nissen SE: Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. Circulation 1995;92:2333–2342.
14.
Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, Jansen H, Boerma GJ, van Rappard FM, Lie KI: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:2528–2540.
15.
Van der Giessen M, Van den Berg AP, van der Bij W, Postma S, Van Son WJ, The TH: Quantitative measurement of cytomegalovirus-specific IgG and IgM antibodies in relation to cytomegalovirus antigenaemia and disease activity in kidney recipients with an active cytomegalovirus infection. Clin Exp Immunol 1990;80:56–61.
16.
Carlsson J, Miketic S, Mueller KH, Brom J, Ross R, Von Essen R, Tebbe U: Previous cytomegalovirus or Chlamydia pneumoniae infection and risk of restenosis after percutaneous transluminal coronary angioplasty. Lancet 1997;350:1225.
17.
Tobis JM, Mallery J Mahon D, Lehmann K, Zalesky P, Griffith J, Gessert J, Moriuchi M, McRae M, Dwyer ML, Greep N, Henry WL: Intravascular ultrasound imaging of human coronary arteries in vivo. Analysis of tissue characterizations with comparison to in vitro histological specimens. Circulation 1991;83:913–926.
18.
Savage MP, Goldberg S, Macdonald RG, Bass TA, Margolis JR, Whitworth HB, Taussig AS, Vetrovec G, Cowley M, Bove AA, Kleaveland P, Hirshfeld JW, Hill JA, Gilmore P, Pepine CJ: Multi-Hospital Eastern Atlantic Restenosis Trial. II. A placebo-controlled trial of thromboxane blockade in the prevention of restenosis following coronary angioplasty. Am Heart J 1991;122:1239–1244.
19.
Topol EJ, Leya F, Pinkerton CA, Whitlow PL, Hofling B, Simonton CA, Masden RR, Serruys PW, Leon MB, Williams DO, King SB3, Mark DB, Isner JM, Holmes DR Jr, Ellis SG, Lee KL, Keeler KP, Berdan LG, Hinohara T, Califf RM: A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. The CAVEAT Study Group. N Engl J Med 1993;329:221–227.
20.
Ono K, Imazu M, Yamabe T, Sumii K, Yamamoto H, Ueda H, Tadehara F, Hayashi Y, Shimamoto F, Yamakido M: Difference of histopathological findings in restenosis lesions after directional coronary atherectomy and balloon angioplasty (abstract). Circulation 1996;94:I728–I729.
21.
Califf RM, Ohman EM, Frid DJ, et al: Restenosis; the clinical issues; in Topol EJ (ed): Textbook of Interventional Cardiology. Philadelphia, Saunders, 1990, pp 363–394.
22.
Quyyumi AA, Raphael M, Perrins EJ, Shapiro LM, Rickards AF, Fox KM: Incidence of spasm at the spite of previous successful transluminal coronary angioplasty: Effect of ergometrine maleate in consecutive patients. Br Heart J 1986;56:27–32.
23.
Gordon PC, Friedrich SP, Piana RN, Kugelmass AD, Leidig GA, Gibson CM, Cohen DJ, Carrozza JP, Kuntz RE, Baim DS: Is 40% to 70% diameter narrowing at the site of previous stenting or directional coronary atherectomy clinically significant? Am J Cardiol 1994;74:26–32.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.